These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 31186274)

  • 41. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
    Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA
    Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
    Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
    Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study.
    Vijenthira A; Chan K; Cheung MC; Prica A
    Lancet Haematol; 2020 Feb; 7(2):e146-e156. PubMed ID: 31948928
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma.
    Castellino SM; Pei Q; Parsons SK; Hodgson D; McCarten K; Horton T; Cho S; Wu Y; Punnett A; Dave H; Henderson TO; Hoppe BS; Charpentier AM; Keller FG; Kelly KM
    N Engl J Med; 2022 Nov; 387(18):1649-1660. PubMed ID: 36322844
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Limited-stage Hodgkin lymphoma: optimal chemotherapy and the role of radiotherapy.
    Bartlett NL
    Am Soc Clin Oncol Educ Book; 2013; ():374-80. PubMed ID: 23714551
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Our experience with the treatment of Hodgkin lymphoma patients].
    Illés Á; Garai I; Miltényi Z
    Orv Hetil; 2023 Mar; 164(11):403-410. PubMed ID: 36934353
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence.
    Seshachalam A; Karpurmath SV; Rathnam K; Raman SG; Janarthinakani M; Prasad K; Patil C; Anoop P; Reddy N; Anumula SK; Roopa SP; Golamari KR; Danthala M; Gunari P; Malipatil B; Rangarajan B; Udupa KS; Nandennavar M; Niraimathi K; Shewade HD
    J Glob Oncol; 2019 Nov; 5():1-13. PubMed ID: 31834832
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy.
    Straus D; Collins G; Walewski J; Zinzani PL; Grigg A; Sureda A; Illes A; Kim TM; Alekseev S; Specht L; Buccheri V; Younes A; Connors J; Forero-Torres A; Fenton K; Gautam A; Purevjal I; Liu R; Gallamini A
    Leuk Lymphoma; 2020 Dec; 61(12):2931-2938. PubMed ID: 32842815
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation.
    Metzger ML; Link MP; Billett AL; Flerlage J; Lucas JT; Mandrell BN; Ehrhardt MJ; Bhakta N; Yock TI; Friedmann AM; de Alarcon P; Luna-Fineman S; Larsen E; Kaste SC; Shulkin B; Lu Z; Li C; Hiniker SM; Donaldson SS; Hudson MM; Krasin MJ
    J Clin Oncol; 2021 Jul; 39(20):2276-2283. PubMed ID: 33826362
    [TBL] [Abstract][Full Text] [Related]  

  • 50. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.
    Meyer RM; Gospodarowicz MK; Connors JM; Pearcey RG; Wells WA; Winter JN; Horning SJ; Dar AR; Shustik C; Stewart DA; Crump M; Djurfeldt MS; Chen BE; Shepherd LE; ;
    N Engl J Med; 2012 Feb; 366(5):399-408. PubMed ID: 22149921
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.
    Hentrich M; Berger M; Wyen C; Siehl J; Rockstroh JK; Müller M; Fätkenheuer G; Seidel E; Nickelsen M; Wolf T; Rieke A; Schürmann D; Schmidmaier R; Planker M; Alt J; Mosthaf F; Engert A; Arasteh K; Hoffmann C
    J Clin Oncol; 2012 Nov; 30(33):4117-23. PubMed ID: 23045592
    [TBL] [Abstract][Full Text] [Related]  

  • 52. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.
    Press OW; Li H; Schöder H; Straus DJ; Moskowitz CH; LeBlanc M; Rimsza LM; Bartlett NL; Evens AM; Mittra ES; LaCasce AS; Sweetenham JW; Barr PM; Fanale MA; Knopp MV; Noy A; Hsi ED; Cook JR; Lechowicz MJ; Gascoyne RD; Leonard JP; Kahl BS; Cheson BD; Fisher RI; Friedberg JW
    J Clin Oncol; 2016 Jun; 34(17):2020-7. PubMed ID: 27069074
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial.
    Carde P; Karrasch M; Fortpied C; Brice P; Khaled H; Casasnovas O; Caillot D; Gaillard I; Bologna S; Ferme C; Lugtenburg PJ; Morschhauser F; Aurer I; Coiffier B; Meyer R; Seftel M; Wolf M; Glimelius B; Sureda A; Mounier N
    J Clin Oncol; 2016 Jun; 34(17):2028-36. PubMed ID: 27114593
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy.
    Chand VK; Link BK; Ritchie JM; Shannon M; Wooldridge JE
    Leuk Lymphoma; 2006 Apr; 47(4):657-63. PubMed ID: 16690524
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up.
    Brusamolino E; Baio A; Orlandi E; Arcaini L; Passamonti F; Griva V; Casagrande W; Pascutto C; Franchini P; Lazzarino M
    Clin Cancer Res; 2006 Nov; 12(21):6487-93. PubMed ID: 17085663
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Initial treatment strategy for classical Hodgkin lymphoma in adults].
    Kusumoto S
    Rinsho Ketsueki; 2021; 62(8):1102-1111. PubMed ID: 34497197
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin's lymphoma: a probabilistic analysis.
    Raymakers AJN; Costa S; Cameron D; Regier DA
    BMC Cancer; 2020 Oct; 20(1):992. PubMed ID: 33050897
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Real-World Use of Positron Emission Tomography-Computed Tomography and Reported Deauville Scores in Advanced-Stage Classic Hodgkin Lymphoma: A Community Oncology Practice Perspective.
    Yasenchak C; Liu N; Beeks A; Fanale M; Robert N; He D; Yu KS
    JCO Oncol Pract; 2023 Oct; 19(10):860-870. PubMed ID: 37651672
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma.
    Russo F; Corazzelli G; Frigeri F; Capobianco G; Aloj L; Volzone F; De Chiara A; Bonelli A; Gatani T; Marcacci G; Donnarumma D; Becchimanzi C; de Lutio E; Ionna F; De Filippi R; Lastoria S; Pinto A
    Br J Haematol; 2014 Jul; 166(1):118-29. PubMed ID: 24673727
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial.
    Iannitto E; Minardi V; Gobbi PG; Calvaruso G; Tripodo C; Marcheselli L; Luminari S; Merli F; Baldini L; Stelitano C; Callea V; Petrini M; Angrilli F; Quarta G; Vallisa D; Molica S; Liardo E; Polimeno G; Brugiatelli M; Federico M
    Clin Lymphoma Myeloma; 2009 Apr; 9(2):138-44. PubMed ID: 19406724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.